NCT05816850 Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
| NCT ID | NCT05816850 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Condition | Follicular Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 654 participants |
| Start Date | 2023-09-19 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 654 participants in total. It began in 2023-09-19 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Multicenter, Retrospective, Biological study ancillary to FOLL12 trial to evaluate the role of EZH2 aberrations in patient with FL treated with immunochemotherapy. Moreover, several novel biomarkers of FL will be investigated.
Eligibility Criteria
Inclusion Criteria: * Patient enrolled in the FIL\_FOLL12 trial (documented by the signature of the study informed consent); * Availability of biological samples: bone marrow aspirate, peripheral blood and/or FFPE diagnostic sample (nodal or extranodal); Exclusion Criteria: * None
Contact & Investigator
Simone Ferrero, MD
PRINCIPAL INVESTIGATOR
SC Ematologia U - AOU Città della Salute e della Scienza di Torino
Frequently Asked Questions
Who can join the NCT05816850 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Follicular Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05816850 currently recruiting?
Yes, NCT05816850 is actively recruiting participants. Contact the research team at startup@filinf.it for enrollment information.
Where is the NCT05816850 trial being conducted?
This trial is being conducted at Alessandria, Italy, Biella, Italy, Brescia, Italy, Catania, Italy and 11 additional locations.
Who is sponsoring the NCT05816850 clinical trial?
NCT05816850 is sponsored by Fondazione Italiana Linfomi - ETS. The principal investigator is Simone Ferrero, MD at SC Ematologia U - AOU Città della Salute e della Scienza di Torino. The trial plans to enroll 654 participants.